- Acquired by Veracyte for $95M, Jan 2024
- Raised $100M Series B led by Casdin Capital, Mar 2021
- Raised $12M Series A led by NFX Capital, May 2020
About
C2i Genomics developed a cancer treatment intelligence platform that uses low-input blood and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. The company's SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging thousands of installed genome sequencers worldwide. C2i Genomics' technology analyzes subtle changes in the tumor's DNA patterns to provide early detection and personalized treatment monitoring. The company's mission was influenced by co-founder Asaf Zviran's personal experience as a cancer survivor. C2i Genomics provides acuity in cancer detection and monitoring by combining whole genome sequencing with a proprietary AI-based tumor enrichment method that recognizes patient-specific cancer patterns.
Funding history · 3 rounds · $113.2M total
Headcount over time
Q&A
- What is C2i Genomics' primary focus?
- C2i Genomics focuses on providing a whole-genome cancer treatment intelligence platform that empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection.
- When was C2i Genomics founded?
- C2i Genomics was founded in August 2019.
- What is C2i Genomics' employee count?
- C2i Genomics has 11-50 employees.
- What is the total amount of funding C2i Genomics has raised?
- C2i Genomics has raised a total of $113,200,000 USD.
- Which investors participated in C2i Genomics' April 2021 funding round?
- In April 2021, C2i Genomics raised $100,000,000 USD in a round led by.
- What is C2i Genomics' current status?
- C2i Genomics was acquired by Veracyte in January 2024.
- Where is C2i Genomics headquartered?
- C2i Genomics is headquartered in Tirat Carmel, Israel.
- What technologies does C2i Genomics utilize?
- C2i Genomics utilizes platforms & interfaces, software, data storage, cloud, artificial intelligence, and machine learning.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | veracyte.com/mrd-technology |
|---|---|
| linkedin.com/company/36105135 |
Identifiers & details
| Legal name | C2i Genomics, Inc. |
|---|---|
| Founded | 2019-8 |
| Employees (exact) | 30 |
| Offices | New York; Cambridge |
| Status reason | Acquired by Veracyte on Jan, 2024 |
Acquisitions & public offerings
Acquired by Veracyte 2024-01 $95.0M
Radar intelligence
Web history (Wayback)
| Domain | veracyte.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516073541 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2019-08-21 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 3 — charge (1), annual_report (1), other (1) |
| Registered address | חת נחום 7 חיפה |
Recent registry events
| Date | Event |
|---|---|
| 2026-03-30 | רישום שעבוד |
| 2025-12-21 | דו~ח שנתי-עדכון כתובת |
| 2026-02-03 | עדכון כתובת ו/או מען דיגיטלי |